An immune-protein score combining TRAIL, IP-10 and CRP for predicting severe COVID-19 disease.
COVID-19 disease severity prediction
Emergency Department
Host-immune protein score
SARS-CoV-2
Journal
Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
13
02
2023
revised:
11
05
2023
accepted:
21
05
2023
medline:
11
8
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
COVID-19 patients are oftentimes over- or under-treated due to a deficit in predictive management tools. This study reports derivation of an algorithm that integrates the host levels of TRAIL, IP-10, and CRP into a single numeric score that is an early indicator of severe outcome for COVID-19 patients and can identify patients at-risk to deteriorate. 394 COVID-19 patients were eligible; 29% meeting a severe outcome (intensive care unit admission/non-invasive or invasive ventilation/death). The score's area under the receiver operating characteristic curve (AUC) was 0.86, superior to IL-6 (AUC 0.77; p = 0.033) and CRP (AUC 0.78; p < 0.001). Likelihood of severe outcome increased significantly (p < 0.001) with higher scores. The score differentiated severe patients who further deteriorated from those who improved (p = 0.004) and projected 14-day survival probabilities (p < 0.001). The score accurately predicted COVID-19 patients at-risk for severe outcome, and therefore has potential to facilitate timely care escalation and de-escalation and appropriate resource allocation.
Identifiants
pubmed: 37327532
pii: S1043-4666(23)00124-2
doi: 10.1016/j.cyto.2023.156246
pmc: PMC10235675
pii:
doi:
Substances chimiques
Chemokine CXCL10
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
156246Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AK, BT, MSt and MSh have indicated that they have no potential conflicts of interest to disclose. AA, EE, ER, ES, KO, MH, MR, NA, NSM, OS, RN, TIB, TMG and YI are/were employees of MeMed and hold stock and/or options; PF holds MeMed stock options; SL declares to have received lecturing fees from MeMed; EE, ES, KO, MH, NSM, OS, RN, SL, TIB, TMG are inventors of pending or issued patent applications relating to the TRAIL/IP-10/CRP technology; AJ, EBC, IK, DD, SL, PS, RK, SM, SAT, GD and CP declare that their medical center received funding from MeMed.